Aastrom Biosciences (ASTM) Higher Ahead of Data
Tweet
Share
E-mailGet Alerts ASTM Hot Sheet
Join SI Premium – FREE
Shares of Aastrom Biosciences (NASDAQ: ASTM) are seeing action Friday after the stock was highlighted as the "next big thing in biotech" by theStreet.com's Adam Feuerstein.
Feuerstein put the spotlight on the stock ahead of data expected Monday at the American Heart Association annual meeting on its personalized stem cell therapy for critical limb ischemia.
Feuerstein expects strong results, although he said this may not be a short-term trading event. He also warns that the company may have to raise money. He does think the company is developing their stem cell therapy the "right way" and has a great chance of success.
Shares of Aastrom are up 5.5 percent today to $2.70 per share.
Video Below:
Feuerstein put the spotlight on the stock ahead of data expected Monday at the American Heart Association annual meeting on its personalized stem cell therapy for critical limb ischemia.
Feuerstein expects strong results, although he said this may not be a short-term trading event. He also warns that the company may have to raise money. He does think the company is developing their stem cell therapy the "right way" and has a great chance of success.
Shares of Aastrom are up 5.5 percent today to $2.70 per share.
Video Below:
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- Novavax's Nuvaxovid wins approval in U.S., EU, Japan for 2026-2027
- FDA approves Gilead's Bixlenvo HIV tablet for adults on complex regimens
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
